8-K: Petros Pharmaceuticals Faces Nasdaq Delisting

Petros Pharmaceuticals, Inc. received notice from Nasdaq regarding the delisting of its common stock, which will continue trading on the OTCID Basic Market.

Summary

• Nasdaq notified Petros Pharmaceuticals, Inc. on November 3, 2025, of its intent to announce the delisting of the company's common stock on November 7, 2025.
• The common stock was suspended from trading on The Nasdaq Capital Market on May 22, 2025, and has been trading on the OTCID Basic Market (OTCID) under the symbol PTPI since July 1, 2025.
• Nasdaq will file a Form 25 with the SEC to complete the delisting, which will deregister the common stock under Section 12(b) of the Exchange Act.
• The delisting will become effective ten days after the Form 25 is filed.
• The common stock will continue trading on the OTCID without disruption, and the company will remain subject to reporting obligations under Sections 13 and 15(d) of the Exchange Act.

Sentiment

Score: 2

Explanation: The delisting from Nasdaq is a highly negative event, indicating significant operational or financial challenges and likely leading to reduced investor confidence and market liquidity.

Positives

• Common stock will continue trading on the OTCID Basic Market without disruption.
• The company will remain subject to reporting obligations under Sections 13 and 15(d) of the Exchange Act, maintaining a level of transparency.

Negatives

• The company's common stock is being delisted from The Nasdaq Stock Market.
• Trading was suspended from The Nasdaq Capital Market on May 22, 2025, prior to the formal delisting announcement.

Risks

• Loss of prestige and visibility associated with a Nasdaq listing.
• Potential decrease in liquidity for the common stock due to trading on the OTCID Basic Market.
• Reduced investor interest and institutional investment due to trading on an over-the-counter market.
• Increased administrative burden and costs associated with managing the delisting process and continued reporting obligations.

Future Outlook

The common stock will continue to trade on the OTCID Basic Market without disruption, and the company will remain subject to its reporting obligations under the Securities Exchange Act of 1934.

Management Comments

• Fady Boctor, President and Chief Commercial Officer, signed the report on behalf of Petros Pharmaceuticals, Inc.

Industry Context

Delistings from major exchanges like Nasdaq typically occur when a company fails to meet listing standards, often related to minimum bid price, market capitalization, or shareholder equity. Such events generally signal financial distress or operational challenges, leading to reduced investor confidence and liquidity compared to peers maintaining major exchange listings.

Comparison to Industry Standards

• Delisting from Nasdaq places Petros Pharmaceuticals, Inc. outside the standards for major exchange-listed pharmaceutical companies, which typically maintain higher liquidity and investor visibility.
• Companies like Pfizer (PFE) or Johnson & Johnson (JNJ) maintain robust listing standards on the NYSE, offering greater investor protections and market access compared to OTC-traded entities.
• The move to the OTCID Basic Market suggests a significant deviation from the operational and financial health expected of publicly traded pharmaceutical firms, potentially impacting its ability to attract capital or strategic partners compared to its Nasdaq-listed counterparts.

Stakeholder Impact

• Shareholders: Likely to experience reduced liquidity and potentially increased volatility in the stock price due to trading on the OTCID Basic Market. The perceived value of their holdings may decrease.
• Investors: May face challenges in trading the stock and could view the company as higher risk due to the delisting from a major exchange.

Next Steps

• Nasdaq will file a Form 25 with the Securities and Exchange Commission to complete the delisting.
• The delisting will become effective ten days after the Form 25 is filed.
• The company's common stock will continue trading on the OTCID Basic Market.

Key Dates

Recommendation

The delisting from Nasdaq is a severe negative indicator, signaling fundamental issues with the company's ability to meet exchange requirements. Trading on the OTCID Basic Market typically results in significantly reduced liquidity, lower investor confidence, and limited institutional interest. This event fundamentally alters the investment profile to a much higher risk category with limited upside potential in the near term, warranting a strong sell recommendation for existing holders and avoidance for new investors.

Keywords

Petros Pharmaceuticals, PTPI, Nasdaq delisting, OTCID Basic Market, SEC filing, Form 8-K, common stock, securities regulation